139 related articles for article (PubMed ID: 35524687)
1. Evaluation of adverse events in small-breed dogs treated with maropitant and a single dose of doxorubicin.
Matsuyama F; Harada K; Fukazawa E; Ichimata M; Nakano Y; Kobayashi T
J Vet Intern Med; 2022 Jul; 36(4):1409-1415. PubMed ID: 35524687
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of maropitant in the prevention of delayed vomiting associated with administration of doxorubicin to dogs.
Rau SE; Barber LG; Burgess KE
J Vet Intern Med; 2010; 24(6):1452-7. PubMed ID: 21039869
[TBL] [Abstract][Full Text] [Related]
3. Assessment of the administration of maropitant and loperamide to dogs with cancer for the prevention and reduction of adverse effects associated with the administration of paclitaxel.
Cartagena-Albertus JC; Engel Manchado J; Moise A; Moya García S; Montoya Alonso JA
Am J Vet Res; 2019 Jun; 80(6):601-606. PubMed ID: 31140850
[TBL] [Abstract][Full Text] [Related]
4. Toxicoses associated with the administration of mitoxantrone to dogs with malignant tumors: a dose escalation study.
Ogilvie GK; Moore AS; Chen C; Ciekot PA; Atwater SW; Bergman PJ; Walters LM
J Am Vet Med Assoc; 1994 Aug; 205(4):570-3. PubMed ID: 7961092
[TBL] [Abstract][Full Text] [Related]
5. Acute and short-term toxicoses associated with the administration of doxorubicin to dogs with malignant tumors.
Ogilvie GK; Richardson RC; Curtis CR; Withrow SJ; Reynolds HA; Norris AM; Henderson RA; Klausner JS; Fowler JD; McCaw D
J Am Vet Med Assoc; 1989 Dec; 195(11):1584-7. PubMed ID: 2599942
[TBL] [Abstract][Full Text] [Related]
6. Effect of dosing interval on efficacy of maropitant for prevention of hydromorphone-induced vomiting and signs of nausea in dogs.
Hay Kraus BL
J Am Vet Med Assoc; 2014 Nov; 245(9):1015-20. PubMed ID: 25313812
[TBL] [Abstract][Full Text] [Related]
7. Effects of maropitant, acepromazine, and electroacupuncture on vomiting associated with administration of morphine in dogs.
Koh RB; Isaza N; Xie H; Cooke K; Robertson SA
J Am Vet Med Assoc; 2014 Apr; 244(7):820-9. PubMed ID: 24649993
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and toxicity of doxorubicin/cyclophosphamide maintenance therapy in dogs with multicentric lymphosarcoma.
Price GS; Page RL; Fischer BM; Levine JF; Gerig TM
J Vet Intern Med; 1991; 5(5):259-62. PubMed ID: 1748977
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of orally administered maropitant citrate in preventing vomiting associated with hydromorphone administration in dogs.
Hay Kraus BL
J Am Vet Med Assoc; 2014 May; 244(10):1164-9. PubMed ID: 24786163
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the antiemetic efficacy of maropitant in dogs medicated with morphine and acepromazine.
Lorenzutti AM; Martín-Flores M; Litterio NJ; Himelfarb MA; Zarazaga MP
Vet Anaesth Analg; 2016 Mar; 43(2):195-8. PubMed ID: 26095960
[TBL] [Abstract][Full Text] [Related]
11. Anti-nausea effects and pharmacokinetics of ondansetron, maropitant and metoclopramide in a low-dose cisplatin model of nausea and vomiting in the dog: a blinded crossover study.
Kenward H; Elliott J; Lee T; Pelligand L
BMC Vet Res; 2017 Aug; 13(1):244. PubMed ID: 28814338
[TBL] [Abstract][Full Text] [Related]
12. Effects of maropitant citrate or acepromazine on the incidence of adverse events associated with hydromorphone premedication in dogs.
Claude AK; Dedeaux A; Chiavaccini L; Hinz S
J Vet Intern Med; 2014; 28(5):1414-7. PubMed ID: 25146756
[TBL] [Abstract][Full Text] [Related]
13. Gastrointestinal toxicity after vincristine or cyclophosphamide administered with or without maropitant in dogs: a prospective randomised controlled study.
Mason SL; Grant IA; Elliott J; Cripps P; Blackwood L
J Small Anim Pract; 2014 Aug; 55(8):391-8. PubMed ID: 24920169
[TBL] [Abstract][Full Text] [Related]
14. Doxorubicin area under the curve is an important predictor of neutropenia in dogs with naturally occurring cancers.
Wittenburg LA; Weishaar K; Ramirez D; Gustafson DL
Vet Comp Oncol; 2019 Jun; 17(2):147-154. PubMed ID: 30638304
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of maropitant for treatment and prevention of emesis caused by intravenous infusion of cisplatin in dogs.
de la Puente-Redondo VA; Tilt N; Rowan TG; Clemence RG
Am J Vet Res; 2007 Jan; 68(1):48-56. PubMed ID: 17199418
[TBL] [Abstract][Full Text] [Related]
16. Toxicoses associated with administration of mitoxantrone to dogs with malignant tumors.
Ogilvie GK; Obradovich JE; Elmslie RE; Vail DM; Moore AS; Curtis CR; Straw RC; Dickinson K; Cooper MF; Withrow SJ
J Am Vet Med Assoc; 1991 May; 198(9):1613-7. PubMed ID: 2061176
[TBL] [Abstract][Full Text] [Related]
17. Maropitant prevented vomiting but not gastroesophageal reflux in anesthetized dogs premedicated with acepromazine-hydromorphone.
Johnson RA
Vet Anaesth Analg; 2014 Jul; 41(4):406-10. PubMed ID: 24330310
[TBL] [Abstract][Full Text] [Related]
18. Safety evaluation of combination doxorubicin and toceranib phosphate (Palladia®) in tumour bearing dogs: a phase I dose-finding study.
Pellin MA; Wouda RM; Robinson K; Tsimbas K; Kurzman ID; Biller BJ; Vail DM
Vet Comp Oncol; 2017 Sep; 15(3):919-931. PubMed ID: 27146577
[TBL] [Abstract][Full Text] [Related]
19. The anti-emetic efficacy of maropitant (Cerenia) in the treatment of ongoing emesis caused by a wide range of underlying clinical aetiologies in canine patients in Europe.
de la Puente-Redondo VA; Siedek EM; Benchaoui HA; Tilt N; Rowan TG; Clemence RG
J Small Anim Pract; 2007 Feb; 48(2):93-8. PubMed ID: 17286662
[TBL] [Abstract][Full Text] [Related]
20. Vincristine-induced adverse events related to body weight in dogs treated for lymphoma.
Sztukowski KE; Yaufman Z; Cook MR; Aarnes TK; Husbands BD
J Vet Intern Med; 2024; 38(3):1686-1692. PubMed ID: 38563346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
